How has been the historical performance of Aurobindo Pharma?

Answer:The historical performance of Aurobindo Pharma shows a consistent growth trajectory in net sales and profits over the years, with net sales reaching 31,723.73 Cr in March 2025, up from 29,001.87 Cr in March 2024 and 24,855.38 Cr in March 2023. The total operating income followed a similar trend, increasing to 31,723.73 Cr in March 2025 from 29,001.87 Cr in March 2024. Operating profit (PBDIT) also saw an upward movement, rising to 7,204.64 Cr in March 2025 compared to 6,400.38 Cr in March 2024. Profit before tax improved to 5,097.98 Cr in March 2025 from 4,397.15 Cr in March 2024, while profit after tax increased to 3,515.26 Cr from 3,186.13 Cr in the same period. The earnings per share (EPS) rose to 60.02 in March 2025, reflecting the company's profitability.

In terms of assets and liabilities, total assets grew to 43,858.87 Cr in March 2024 from 39,212.50 Cr in March 2023, with total liabilities also increasing to 43,858.87 Cr in March 2024. The company's cash flow from operating activities was 2,434.00 Cr in March 2024, slightly up from 2,386.00 Cr in March 2023, while cash flow from investing activities showed a negative trend at -4,241.00 Cr in March 2024. Overall, Aurobindo Pharma's financial metrics indicate a robust performance with steady growth in sales and profitability, despite fluctuations in cash flow from investing activities.

Breakdown:
Aurobindo Pharma's financial performance has demonstrated significant growth over the years, particularly in net sales, which increased from 24,855.38 Cr in March 2023 to 31,723.73 Cr in March 2025. This growth is mirrored in total operating income, which also rose to 31,723.73 Cr in March 2025. Operating profit (PBDIT) saw a notable increase to 7,204.64 Cr in March 2025, up from 4,009.23 Cr in March 2023, indicating improved operational efficiency. Profit before tax and profit after tax followed suit, reaching 5,097.98 Cr and 3,515.26 Cr respectively in March 2025, showcasing the company's ability to enhance profitability. The earnings per share (EPS) also reflected this positive trend, climbing to 60.02 in March 2025. On the balance sheet, total assets grew to 43,858.87 Cr in March 2024, while total liabilities increased correspondingly, indicating a balanced growth in the company's financial structure. Cash flow from operating activities remained stable, suggesting consistent operational cash generation, although cash flow from investing activities showed a negative trend, indicating increased investments or capital expenditures. Overall, Aurobindo Pharma's financial metrics highlight a strong and growing business performance.